文献速递核素与放射性配体治疗肿瘤 PET/CT

VLA-4靶向放射核素治疗联合免疫检查点抑制剂在黑色素瘤小鼠模型中的疗效

Combined VLA-4-Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma.
PubMed 文献 · J Nucl Med · 2018-06-29

研究评估了177Lu-DOTA-PEG4-LLP2A(靶向VLA-4的放射核素治疗)单用及联合免疫检查点抑制剂(抗PD-1、抗PD-L1、抗CTLA-4抗体)在B16F10黑色素瘤荷瘤小鼠中的疗效。结果显示,单用放射核素治疗的疗效与双免疫检查点抑制剂相当,而联合治疗显著提高了生存率,且联合组凋亡水平最高。放射核素治疗除靶向肿瘤细胞外,还结合肿瘤微环境中的免疫细胞,提示联合方案对转移性黑色素瘤具有治疗潜力。

要点

  • 单用177Lu-LLP2A的疗效与抗PD-1+抗CTLA-4或抗PD-L1+抗CTLA-4双免疫检查点抑制剂相当。
  • 177Lu-LLP2A联合免疫检查点抑制剂显著增强生存,联合组凋亡水平最高。
  • 放射核素治疗还结合肿瘤微环境中VLA-4高表达的免疫细胞(巨噬细胞、T细胞、B细胞)。

核心结论

  • 放射核素治疗联合免疫检查点抑制剂同时靶向肿瘤细胞和免疫细胞,具有作为转移性黑色素瘤患者治疗药物的潜力。

研究设计与样本

  • 将1×10^6个B16F10肿瘤细胞皮下植入C57BL/6小鼠,8-10天后随机分为8组。
  • 第8或9天静脉注射单剂177Lu-LLP2A,腹腔注射3剂免疫检查点抑制剂抗体(抗PD-1、抗PD-L1、抗CTLA-4)。
  • 用卡尺监测肿瘤生长,对固定肿瘤进行TUNEL染色检测凋亡。
  • 另设研究注射Cy3-LLP2A或Cy3-scrambled LLP2A,注射后4小时收集肿瘤,用流式细胞术和免疫荧光显微镜分析免疫细胞标志物。

主要发现

  • 单用放射核素治疗的疗效与双免疫检查点抑制剂(抗PD-1+抗CTLA-4或抗PD-L1+抗CTLA-4)相当。
  • 放射核素治疗联合免疫检查点抑制剂显著增强生存。
  • TUNEL染色显示凋亡水平最高见于放射核素治疗联合免疫检查点抑制剂组。
  • 流式细胞术显示肿瘤中约77%为肿瘤细胞和成纤维细胞(CD45阴性/CD49d阳性),约23%为免疫细胞(CD45阳性/CD49d阳性),免疫细胞VLA-4表达更高。
  • Cy3-LLP2A与CD49d共定位于巨噬细胞(CD68)、T细胞(CD8、CD4)和B细胞(CD19),免疫组化分析发现Cy3-LLP2A与CD68显著共定位。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Very late antigen-4 (VLA-4; also known as integrin α4β1) is expressed at high levels in aggressive and metastatic melanoma tumors and may provide an ideal target for imaging and targeted radionuclide therapy (TRT). 177Lu-DOTA-PEG4-LLP2A (177Lu-LLP2A) is a TRT that shows high affinity for VLA-4 and high uptake in B16F10 mouse melanoma tumors in vivo. Here, we report efficacy studies of 177Lu-LLP2A, alone and combined with immune checkpoint inhibitors (ICIs) (anti-PD-1, anti-PD-L1, and anti-CTLA-4 antibodies), in B16F10 tumor-bearing mice. Methods: Tumor cells (1 × 106) were implanted subcutaneously in C57BL/6 mice. After 8-10 d, the mice were randomized into 8 groups. 177Lu-LLP2A was injected intravenously on day 8 or 9 (single dose), and ICI antibodies were administered intraperitoneally in 3 doses. Tumor growth was monitored over time via calipers. Terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) staining for apoptosis was performed on fixed tumors. In a separate study, Cy3-LLP2A or Cy3-scrambled LLP2A was injected in tumor-bearing mice, and tumors were collected 4 h after injection and then analyzed by flow cytometry and immunofluorescence microscopy using different immune cell markers. Results: TRT alone showed efficacy comparable to the dual-ICI anti-PD-1 + anti-CTLA-4 or anti-PD-L1 + anti-CTLA-4, whereas TRT + ICIs significantly enhanced survival. TUNEL staining showed that the highest levels of apoptosis were in the TRT + ICI groups. In addition to targeting tumor cells, TRT also bound immune cells in the tumor microenvironment. Flow cytometry data showed that the tumors consisted of about 77% tumor cells and fibroblasts (CD45-negative/CD49d-positive) and about 23% immune cells (CD45-positive/CD49d-positive) and that immune cells expressed higher levels of VLA-4. Cy3-LLP2A and CD49d colocalized with macrophages (CD68), T cells (CD8, CD4), and B cells (CD19). Immunohistochemical analysis identified a significant colocalization of Cy3-LLP2A and CD68. Conclusion: Combination treatment with TRT + ICIs targets both tumor cells and immune cells and has potential as a therapeutic agent in patients with metastatic melanoma.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Choi J, Beaino W, Fecek RJ, et al. Combined VLA-4-Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma. J Nucl Med. 2018. PMID: 29959213. doi:10.2967/jnumed.118.209510

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。